1. Medtech Insight
  2. >>Business
  3. >>Startups & SMEs

EuroPCR 2017: Xeltis' Regenerated Heart Valve Shows Promising Early Preclinical Data

 
• By Catherine Longworth

It may still be early days but Xeltis' second product from its Endogenous Tissue Restoration platform technology, an aortic valve scaffold, is showing promising results in animal studies. The data, presented at EuroPCR, showed that the bioresorbable aortic valve had good hemodynamic performance and fully functional valves in vivo six months after implantation.

Anatomy of Human Heart
Xeltis presented positive early data from preclinical studies at EuroPCR in Paris • Source: Shutterstock

Emerging structural heart disease specialist Xeltis has presented positive early data from preclinical studies that showed its bioabsorbable aortic heart valve implant was "fully functional" in vivo six-months after implantation. These results were presented at a dedicated plenary session on bioresorbable valve therapy at EuroPCR on May 17 in Paris.

Laurent Grandidier, CEO of Xeltis told Medtech Insight the results were

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Startups & SMEs

More from Business

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.